Botulinum toxin treatment of anxiety and bipolar disorders

• US 9,238,061 B2
• Filed: 11/21/2013
• Issued: 01/19/2016
• Est. Priority Date: 10/29/2003
• Status: Expired due to Fees

• Current Assignee: Allergan Incorporated (Abbvie Incorporated)
• Original Assignee: Allergan Incorporated (Abbvie Incorporated)
• Inventors: Blumenfeld, Andrew M.
• Primary Examiner(s): Emch, Gregory S
• Application Number:
  US14/086,086
• Publication Number:
  US 20140099298A1
• Time in Patent Office: 789 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 38/4893 Botulinum neurotoxin (3.4.24.69)
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 25/24 Antidepressants

Abstract

Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression.

Claims

1. A method for treating an anxiety disorder in a patient in need thereof, comprising directly administering a botulinum toxin to a trigeminal nerve of the patient, thereby treating the anxiety disorder.

2. The method of claim 1, wherein the botulinum toxin is botulinum toxin type A.

3. The method of claim 1, wherein the botulinum toxin is botulinum toxin type B.

4. The method of claim 1, wherein the method of local administration is injection.

5. The method of claim 1, wherein the administering is by non-intramuscular injection.

6. The method of claim 1, wherein the administering is subdermal, intradermal or transdermal.

7. The method of claim 1, wherein the trigeminal nerve is selected from the group consisting of an ophthalmic nerve, maxillary nerve, mandibular nerve, supra orbital nerve, supra trochlear nerve, infraorbital nerve, lacrimal nerve, nasociliary nerve, superior alveolar nerve, buccal nerve, lingual nerve, inferior alveolar nerve, mental nerve, an auriculotemporal nerve, lesser occipital nerve and a greater occipital nerve.

8. A method for reducing the occurrence of a symptom of anxiety disorder in a patient with anxiety disorder, the method comprising locally administering a therapeutically effective amount of a botulinum toxin non-intramuscularly to a trigeminal sensory nerve or to the vicinity of a trigeminal sensory nerve of the patient, thereby reducing the occurrence of a symptom of anxiety disorder, wherein the administering is subdermal, intradermal or transdermal.

9. The method of claim 8, wherein the botulinum toxin is botulinum toxin type A.

10. The method of claim 8, wherein the botulinum toxin is botulinum toxin type B.

11. The method of claim 8, wherein the method of local administration is injection.

12. The method of claim 8, wherein the administering is by non-intramuscular injection.

13. The method of claim 8, wherein the administering is subdermal.

14. The method of claim 8, wherein the therapeutically effective amount of the botulinum toxin administered is between about 1 unit and about 3,000 units.

15. The method of claim 8, wherein the trigeminal sensory nerve is selected from the group consisting of an ophthalmic nerve, maxillary nerve, mandibular nerve, supra orbital nerve, supra trochlear nerve, infraorbital nerve, lacrimal nerve, nasociliary nerve, superior alveolar nerve, buccal nerve, lingual nerve, inferior alveolar nerve, mental nerve, an auriculotemporal nerve, lesser occipital nerve and a greater occipital nerve.

16. A method for treating bipolar disorder in a patient in need thereof, comprising locally administering a botulinum toxin non-intramuscularly to a trigeminal nerve of the patient, thereby treating the bipolar disorder, wherein the administering is subdermal, intradermal or transdermal.

17. The method of claim 16, wherein the botulinum toxin is botulinum toxin type A.

18. The method of claim 16, wherein the method of local administration is injection.

19. The method of claim 16, wherein the botulinum toxin is botulinum toxin type B.

20. The method of claim 16, wherein the trigeminal nerve is selected from the group consisting of an ophthalmic nerve, maxillary nerve, mandibular nerve, supra orbital nerve, supra trochlear nerve, infraorbital nerve, lacrimal nerve, nasociliary nerve, superior alveolar nerve, buccal nerve, lingual nerve, inferior alveolar nerve, mental nerve, an auriculotemporal nerve, lesser occipital nerve and a greater occipital nerve.